EP1339404A2 - Composition and method - Google Patents

Composition and method

Info

Publication number
EP1339404A2
EP1339404A2 EP01992146A EP01992146A EP1339404A2 EP 1339404 A2 EP1339404 A2 EP 1339404A2 EP 01992146 A EP01992146 A EP 01992146A EP 01992146 A EP01992146 A EP 01992146A EP 1339404 A2 EP1339404 A2 EP 1339404A2
Authority
EP
European Patent Office
Prior art keywords
day
deterioration
cognitive function
composition
accordance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01992146A
Other languages
German (de)
French (fr)
Inventor
Steven Curtis Zicker
Karen J. Wedekind
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Colgate Palmolive Co
Original Assignee
Colgate Palmolive Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/922,633 external-priority patent/US20020052402A1/en
Application filed by Colgate Palmolive Co filed Critical Colgate Palmolive Co
Publication of EP1339404A2 publication Critical patent/EP1339404A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • This deterioration of cognitive function in older humans can now be prevented, inhibited or treated with specific components. These components can be administered in the diet or taken separately orally.
  • composition comprising an antioxidant or mixture thereof quantities sufficient to a. prevent or b. inhibit, or r c. reverse deterioration of cognitive function
  • a further aspect is a method of preventing, inhibiting or reversing deterioration of cognitive function through the administration of this composition.
  • an antioxidant is a material that quenches a free radical.
  • examples of such materials are beta-carotene, selenium, coenzyme Q10 (ubiquinone), lutein, tocotrienols, soy isoflavones, S-adenosylmethionine, glutathione, taurine, N-acetylcysteine, Vitamin E, Vitamin C, alpha-lipoic acid, 1- carnitine and the like.
  • Vitamin E can be administered as a tocopherol or a mixture of tocopherols and various derivatives thereof such as esters like Vitamin E acetate, succinate, palmitate, and the like.
  • the alpha form is preferable but beta, gamma and delta forms can be included.
  • the d form is preferable but racemic mixtures are acceptable.
  • the forms and derivatives will function in a Vitamin E like activity after ingestion.
  • Vitamin C can be administered as ascorbic acid and its various derivatives thereof such as calcium phosphate salts, cholesteryl salt, 2-monophosphate, and the like which will function in a vitamin C like activity after ingesting by the human. They can be in any form such as liquid, semisolid, solid and heat stable form.
  • Alpha-lipoic acid can be administered as alpha lipoic acid or as a lipoate derivative as in US Patent 5,621, 117, racemic mixtures, salts, esters or amides thereof.
  • L-carnitine and various derivatives of carnitine such as the salts such as the hydrochloride, fumarate and succinate s, as well as acetylated carnitine, and the like can be used.
  • the quantities administered to the human are calculated as the active material, per se, that is measured as specific material.
  • the minimum amounts employed should not bring about toxicity.
  • Vitamin E minimum is about 50 or 100 or 150 mg/day. Generally, no more than about 2,000 or desirably about 1,000 or about 750 mg/day can be employed.
  • Vitamin C minimum quantities are generally about 150, about 200 or about 250 mg/day. Maximums generally do not exceed about 1,000 mg/day but can be lower, for example, about 900 or about 750 mg/day.
  • Alpha lipoic acid can be administered up to about 10 or 20 mg/kg body weight/ day. Minimums are about .5 or 1 mg/kg body weight/ day.
  • L-carnitine is administered in the same manner as alpha lipoic acid. Alpha lipoic acid and l-carnitine can be administered at much higher levels but there is no substantially different efficacy observed.
  • Beta-carotene at least about 0.02 mg/kg body weight/ day 1-15 ppm can be employed.
  • Lutein at least about 5 ppm mg/kg body weight/ day can be employed.
  • Tocotrienols at least about 0.5 mg/kg body weight/ day can be employed.
  • Coenzyme Q10 at least about 0.5 mg/kg body weight/ day can be employed.
  • S-adenosylmethionine at least about 1.0 mg/kg body weight/ day can be employed.
  • Taurine at least about 10 mg/kg body weight/ day can be employed.
  • Soy isoflavones at least about 0.5 mg/kg body weight/ day can be used.
  • N-acetylcysteine at least about 1.0 mg/kg/ body weight/ day can be used.
  • Glutathione at least about 1.0 g/kg body weight/ day can be used.
  • Ginkgo Biloba at least 1.0 mg/kg body weight/ day can be used.
  • the quantities can be administered in a typical "one a day" dosage similar to a vitamin. It can be administered in tablet, capsule, caplet for example, or in a liquid carrier form all for ingestion by the human. Additionally, the daily dosage can be broken down into two, three, or four dosage unit forms for convenience or other reasons. Additionally, it can be administered in a food such as snack bars, cereals, and the like.
  • Example 1
  • a supplement or food providing 750 mg vitamin E, 250 mg/ vitamin C, 200 mg lipoic acid and 400 mg of l-carnitine is eaten by an adult human on a daily basis for 5 years starting at age 45.
  • age of 50 no signs of mental deterioration such as disorientation, memory loss, learning impairment, or ability to cope independently with their environmental living situation, classified by objective (or nonobjective) tests such as Folstein's Mini-mental State Exam (MME), Logical Memory and Visual Reproduction tests from the Wechsler Memory Scale (WMS), Katz' scale of activities of daily living, Lawton's scale of instrumental activities of daily living, Pfeiffer's mental status questionnaire, or other pertinent tests as diagnosed by themselves, a care-giver, or health care provider, are observed.
  • MME Folstein's Mini-mental State Exam
  • WMS Wechsler Memory Scale
  • Katz' scale of activities of daily living Lawton's scale of instrumental activities of daily living
  • Pfeiffer's mental status questionnaire or other pertinent tests as
  • MME Folstein's Mini-mental State Exam
  • WMS Wechsler Memory Scale
  • Katz' scale of activities of daily living Lawton's scale of instrumental activities of daily living

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Birds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A composition comprising an antioxidant or mixture thereof in quantities sufficient to prevent, or inhibit, or reverse deterioration of cognitive function.

Description

COMPOSITION AND METHOD
Background Of The Invention
As humans age their mental faculties appear to lessen. This applies to humans in general and is not related to specific conditions such as Alzheimer's and other known-specific disease conditions affecting mental capacity. Memory is not as good as it once was. Learning certain tasks can take a longer time. These types of mental changes are some times associated with or referred to as "old age". Fairly recently this general area is known as cognitive function deterioration and in more generic terms as diminished mental capacity.
This deterioration of cognitive function in older humans can now be prevented, inhibited or treated with specific components. These components can be administered in the diet or taken separately orally.
Summary Of The Invention
In accordance with the invention there is a composition comprising an antioxidant or mixture thereof quantities sufficient to a. prevent or b. inhibit, or r c. reverse deterioration of cognitive function,
A further aspect is a method of preventing, inhibiting or reversing deterioration of cognitive function through the administration of this composition.
Detailed Description Of The Invention Humans can start having deterioration in cognitive function as early as about 50 but generally it can become noticeable at 60, or 70 years of age.
As used in this application, the component(s) that accomplish this are an antioxidant or mixture thereof. An antioxidant is a material that quenches a free radical. Examples of such materials are beta-carotene, selenium, coenzyme Q10 (ubiquinone), lutein, tocotrienols, soy isoflavones, S-adenosylmethionine, glutathione, taurine, N-acetylcysteine, Vitamin E, Vitamin C, alpha-lipoic acid, 1- carnitine and the like. Vitamin E can be administered as a tocopherol or a mixture of tocopherols and various derivatives thereof such as esters like Vitamin E acetate, succinate, palmitate, and the like. The alpha form is preferable but beta, gamma and delta forms can be included. The d form is preferable but racemic mixtures are acceptable. The forms and derivatives will function in a Vitamin E like activity after ingestion. . Vitamin C can be administered as ascorbic acid and its various derivatives thereof such as calcium phosphate salts, cholesteryl salt, 2-monophosphate, and the like which will function in a vitamin C like activity after ingesting by the human. They can be in any form such as liquid, semisolid, solid and heat stable form. Alpha-lipoic acid can be administered as alpha lipoic acid or as a lipoate derivative as in US Patent 5,621, 117, racemic mixtures, salts, esters or amides thereof. L-carnitine and various derivatives of carnitine such as the salts such as the hydrochloride, fumarate and succinate s, as well as acetylated carnitine, and the like can be used.
The quantities administered to the human are calculated as the active material, per se, that is measured as specific material. The minimum amounts employed should not bring about toxicity. Vitamin E minimum is about 50 or 100 or 150 mg/day. Generally, no more than about 2,000 or desirably about 1,000 or about 750 mg/day can be employed. Vitamin C minimum quantities are generally about 150, about 200 or about 250 mg/day. Maximums generally do not exceed about 1,000 mg/day but can be lower, for example, about 900 or about 750 mg/day. Alpha lipoic acid can be administered up to about 10 or 20 mg/kg body weight/ day. Minimums are about .5 or 1 mg/kg body weight/ day. L-carnitine is administered in the same manner as alpha lipoic acid. Alpha lipoic acid and l-carnitine can be administered at much higher levels but there is no substantially different efficacy observed.
Additional antioxidants and their quantities are given in mg/kg body weight/ day numbers.
Beta-carotene at least about 0.02 mg/kg body weight/ day 1-15 ppm can be employed.
Selenium at about 0.02 mg/kg body weight/ day up to 5 ppm can be employed.
Lutein at least about 5 ppm mg/kg body weight/ day can be employed. Tocotrienols at least about 0.5 mg/kg body weight/ day can be employed.
Coenzyme Q10 at least about 0.5 mg/kg body weight/ day can be employed.
S-adenosylmethionine at least about 1.0 mg/kg body weight/ day can be employed.
Taurine at least about 10 mg/kg body weight/ day can be employed. Soy isoflavones at least about 0.5 mg/kg body weight/ day can be used.
N-acetylcysteine at least about 1.0 mg/kg/ body weight/ day can be used.
Glutathione at least about 1.0 g/kg body weight/ day can be used. Ginkgo Biloba at least 1.0 mg/kg body weight/ day can be used.
The quantities can be administered in a typical "one a day" dosage similar to a vitamin. It can be administered in tablet, capsule, caplet for example, or in a liquid carrier form all for ingestion by the human. Additionally, the daily dosage can be broken down into two, three, or four dosage unit forms for convenience or other reasons. Additionally, it can be administered in a food such as snack bars, cereals, and the like. Example 1
A supplement or food providing 750 mg vitamin E, 250 mg/ vitamin C, 200 mg lipoic acid and 400 mg of l-carnitine is eaten by an adult human on a daily basis for 5 years starting at age 45. By the age of 50 no signs of mental deterioration such as disorientation, memory loss, learning impairment, or ability to cope independently with their environmental living situation, classified by objective (or nonobjective) tests such as Folstein's Mini-mental State Exam (MME), Logical Memory and Visual Reproduction tests from the Wechsler Memory Scale (WMS), Katz' scale of activities of daily living, Lawton's scale of instrumental activities of daily living, Pfeiffer's mental status questionnaire, or other pertinent tests as diagnosed by themselves, a care-giver, or health care provider, are observed.
Example 2
An adult human having signs of mental deterioration, such as disorientation, memory loss, learning impairment, or ability to cope independently with their environmental living situation, as classified by objective (or nonobjective) tests such as Folstein's Mini-mental State Exam (MME), Logical Memory and Visual Reproduction tests from the Wechsler Memory Scale (WMS), Katz' scale of activities of daily living, Lawton's scale of instrumental activities of daily living, Pfeiffer's mental status questionnaire, or other pertinent tests as diagnosed by themselves, a care-giver, or a health care provider, is provided a daily food or supplement providing 750 mg vitamin E, 250 mg/ vitamin C, 200 mg lipoic acid and 400 mg of l-carnitine on a daily basis for 1 year. After one year of dosing the above signs are significantly reduced. Example 3
An adult human having signs of mental deterioration such as disorientation, memory loss, learning impairment, or ability to cope independently with their environmental living situation, as classified by objective (or nonobjective) tests such as Folstein's Mini-mental State Exam (MME), Logical Memory and Visual Reproduction tests from the Wechsler Memory Scale (WMS), Katz' scale of activities of daily living, Lawton's scale of instrumental activities of daily living, Pfeiffer's mental status questionnaire, or other pertinent tests as diagnosed by themselves, a care-giver, or a health care provider, is provided a daily food or supplement providing 750 mg vitamin E, 250 mg/ vitamin C, 200 mg lipoic acid and 400 mg of l-carnitine on a daily basis for 2 years. After 2 years of dosing the aforementioned signs have essentially disappeared.

Claims

ClaimsWhat is claimed is:
1. A composition comprising an antioxidant or mixture thereof in quantities sufficient to
a. prevent, or b. inhibit, or c. reverse deterioration of cognitive function.
The composition m accordance with claim 1 wherein deterioration of cognitive function is prevented.
The composition in accordance with claim 1 wherein deterioration of cognitive function is inhibited.
The composition in accordance with claim 1 wherein deterioration of cognitive function is reversed.
5. The composition in accordance with claim 1 wherein Vitamin E is at least about 50 mg/day, Vitamin C is at least about 150 mg/day, l-carnitine is at least about 0.5 mg/kg body weight/ day, and alpha lipoic acid is at least about 0.5 mg/kg body weight/ day.
6. A method for preventing or inhibiting or reversing deterioration of cognitive function in a human which comprises administering a composition of claim 1 to said human.
7. The method in accordance with claim 6 wherein the human is in need of said administering.
8. The method in accordance with claim 6 wherein the deterioration of cognitive function is prevented.
. The method in accordance with claim 6 wherein the deterioration of cognitive function is inhibited.
10. The method in accordance with claim 6 wherein the deterioration of cognitive function is reversed.
EP01992146A 2000-10-31 2001-10-30 Composition and method Withdrawn EP1339404A2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US922633 1986-10-24
US24451100P 2000-10-31 2000-10-31
US244511P 2000-10-31
US25344600P 2000-11-28 2000-11-28
US25344700P 2000-11-28 2000-11-28
US253446P 2000-11-28
US253447P 2000-11-28
US09/922,633 US20020052402A1 (en) 2000-10-31 2001-08-06 Composition and method
PCT/US2001/048665 WO2002043666A2 (en) 2000-10-31 2001-10-30 Compositions containing an antioxidant such as alpha lipoic acid, carnitine, vitamin c or vitamin e for preventing or inhibiting loss of cognitive function

Publications (1)

Publication Number Publication Date
EP1339404A2 true EP1339404A2 (en) 2003-09-03

Family

ID=27500158

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01992146A Withdrawn EP1339404A2 (en) 2000-10-31 2001-10-30 Composition and method

Country Status (6)

Country Link
EP (1) EP1339404A2 (en)
JP (1) JP2004514686A (en)
CN (1) CN1477958A (en)
AU (1) AU2002232616A1 (en)
CA (1) CA2427470A1 (en)
WO (1) WO2002043666A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2239404C1 (en) * 2003-09-17 2004-11-10 Бессонов Дмитрий Михайлович Method for preventing human body aging
JP2005185188A (en) * 2003-12-25 2005-07-14 Nichirei Corp Processed acerola and composition containing L-carnitine
PT1711070E (en) * 2004-01-28 2016-02-15 Nestec Sa Nutritional composiition for improving skin condition and preventing skin diseases
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
EP1817058B1 (en) * 2004-11-24 2015-09-02 Hill's Pet Nutrition, Inc. Composition for use in improving liver clearance of xenobiotic substances in an animal
JP5138380B2 (en) * 2004-11-24 2013-02-06 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド Methods for increasing immune responses in animals
CN101287460B (en) * 2005-08-17 2012-04-25 希尔氏宠物营养品公司 Composition for preventing and treating kidney disease
CN1895671B (en) * 2005-12-08 2012-11-28 淮北辉克药业有限公司 Compound preparation for treating viral liver disease
CN101045048B (en) * 2006-03-27 2011-05-18 中国科学院上海生命科学研究院 Application of chondriosome nutrient composition
WO2008099469A1 (en) * 2007-02-14 2008-08-21 Tohoku University Composition and method for suppressing lipid peroxidation in erythrocytes
EP2453759B1 (en) * 2009-07-14 2015-10-21 Hill's Pet Nutrition, Inc. Pet food compositions including a sustained-release lipoic acid and methods of manufacture and use thereof
EP2508179A1 (en) 2011-04-05 2012-10-10 Lonza Ltd. Use of L-Carnitine, salts and derivatives thereof for reducing or preventing fatigue and improving cognitive function
KR20140019827A (en) 2011-04-05 2014-02-17 론자 아게 (론자 엘티디.) Use of l-carnitine, salts and derivatives thereof for reducing or preventing fatigue and improving cognitive function
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06199690A (en) * 1992-03-06 1994-07-19 Yunie:Kk Agent for promoting cerebral metabolism and improving cerebral function
DE4343592C2 (en) * 1993-12-21 1998-04-16 Asta Medica Ag Use of R - (+) - alpha-lipoic acid and its metabolites in the form of the free acid or as salts or esters or amides for the treatment of glucose metabolic disorders in the central nervous system
FR2721516B1 (en) * 1994-06-27 1996-09-13 Inst Rech Biolog Sa New uses of a complex based on brain phospholipids in therapy and in food.
US5977162A (en) * 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
IT1302307B1 (en) * 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa COMPOSITION WITH ANTIOXIDANT ACTIVITY AND FOR IMPROVING THE METABOLIC USE OF GLUCOSE, INCLUDING ACETYL
ES2204531T3 (en) * 1999-03-16 2004-05-01 Merck Patent Gmbh COMPOSITION THAT INCLUDES ISOQUERCETINA AND ASCORBIC ACID IN A SUSTAINED RELEASE FORM.
WO2000057876A1 (en) * 1999-03-26 2000-10-05 Lipogenics, Inc. Novel antioxidant formulations and methods for using them
DE19920316A1 (en) * 1999-05-03 1999-12-09 Heinz Kiefer Antioxidant medicament containing vitamins and trace elements, useful e.g. for maintaining cellular function and preventing cancer
AU768189B2 (en) * 1999-06-15 2003-12-04 Nutri-Logics, Inc. Nutrient formulations for disease reduction, and related treatment and component screening methods
JP2003513039A (en) * 1999-11-03 2003-04-08 ジュヴェノン インコーポレイテッド How to treat benign amnesia
US20010043983A1 (en) * 2000-01-25 2001-11-22 Hamilton Nathan D. Nutritional supplements for aged pets
HU227182B1 (en) * 2000-03-06 2010-09-28 Andras Javor Lecitin-ascorbic acid combination

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M.H. BEERS, R. BERKOW: "The Merck Manual of Diagnosis and Therapy, Seventeenth Edition", 1999, MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION, N.J. *
See also references of WO0243666A3 *

Also Published As

Publication number Publication date
JP2004514686A (en) 2004-05-20
WO2002043666A2 (en) 2002-06-06
CA2427470A1 (en) 2002-06-06
WO2002043666A3 (en) 2003-01-30
CN1477958A (en) 2004-02-25
AU2002232616A1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
EP1339404A2 (en) Composition and method
US7015245B2 (en) Formulation to enhance antioxidant potency of Vitamin E
US6121249A (en) Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins
EP1339292B2 (en) Companion pet diet
US6323188B1 (en) Treatment and prevention of cardiovascular diseases, heart attack, and stroke, primary and subsequent, with help of aspirin and certain vitamins
US20130045193A1 (en) Compositions and methods for the prevention of cardiovascular disease
US20060116334A1 (en) Folate based composition for treatment of the cardiovascular system
US20020172721A1 (en) Vitamin formulation for cardiovascular health
EP2859896B1 (en) Pharmaceutical compositions for the treatment of muscular disorders
ES2546055T3 (en) Nutritional supplements for individuals 50 years or older to improve vitality, immunity, eye and bone health
BRPI0620210A2 (en) composition and processes for inhibiting the progression of macular degeneration and promoting healthy vision
EP1248609A1 (en) Method of treating benign forgetfulness
US20130084272A1 (en) Compositions, kits and methods for nutritional supplementation with twelve carbon chain fatty acids and twelve carbon chain acylglycerols
AU2025204524A1 (en) Optimised dosage of diaminophenothiazines in populations
EP3884937A1 (en) Compounds and compositions for the treatment of muscular disorders
WO2014011676A1 (en) Prevention of alcohol reaction with dietary supplements
JP2008214338A (en) Higher brain function lowering agent and delayed memory lowering agent
KR20070111478A (en) Compositions and Methods for Nutritional Supplements
US20020052402A1 (en) Composition and method
US6919330B2 (en) Formulations of drugs
US20080241119A1 (en) Micronutrient formulations for pulmonary and heart health
BR112020016923A2 (en) METHOD FOR REVERSING OR ATTENDING INJURY, OR WEAKNESS OR BONE LOSS, OR TO AVOID FRACTURES IN AN INDIVIDUAL, AND, COMPOSITION
EP1036510B1 (en) Vitamin formulation for cardiovascular health
US20110274791A1 (en) Multivitamin/mineral formulation to combat the effects of environmental stress; improved immunity and improve energy while addressing vitamin and mineral deficiencies without the negative side effects of a mega dose nutritional supplement
ZA200303749B (en) Compositions containing an antioxidant such as alpha lipoic acid, carnitine, Vitamin C or Vitamin E for preventing or inhibiting loss of cognitive function.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030528

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20040430

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061228